Advances in Gastric Cancer and Peritoneal Diseases

Dear Colleagues,

Peritoneal disease can be the most frequent type of metastasis and site of recurrence in patients with advanced gastric cancer. This being the case, treatments of peritoneal disease should be the key for the improvement of prognoses for these patients. For years, we have focused on Stage IV gastric cancer with peritoneal disease. The intraperitoneal administration of paclitaxel (IP-PTX) has a great medical advantage in controlling peritoneal lesions and can be combined with various systemic chemotherapies.

Hyperthermic intraperitoneal chemotherapy (HIPEC), combined with cytoreductive surgery, has been tried for patients with PM of GC mainly in Western countries. These aggressive treatments have not resulted in significant survival benefits in GC patients with PM. Since the intraperitoneal administration of anticancer drugs can induce an extremely high concentration of drugs in the peritoneal cavity, intraperitoneal chemotherapy would appear to be a reasonable and promising strategy with which to control peritoneal dissemination.

This Special Issue aims to highlight the current knowledge on gastric cancer and peritoneal diseases and underline possible diagnostic as well as therapeutic repercussions in gastric cancer and peritoneal diseases.

Dr. Shin Saito
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• gastric cancer
• peritoneal disease
• conversion surgery
• intraperitoneal chemotherapy
• potential biomarker